Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer

Inclusion Criteria

• •1\. Patients must have histologically or cytologically confirmed adenocarcinoma of the pancreas. The site of the primary lesion should be confirmed endoscopically, radiologically, or surgically to be in the pancreas.
• •2\. Patients must be deemed unresectable due to involvement of critical vasculature, adjacent organ invasion, presence of metastasis, or other medical condition making surgical resection unfavorable.
• •3\. Patients must have a primary or metastatic lesion measurable in at least one dimension by RECIST criteria within 4 weeks prior to entry of study .
• •4\. More than 4 weeks must have elapsed from the time of major surgery or completion of the last dose of chemotherapy, radiation therapy, investigational therapy and patients must adequately recover from these effects.
• •5\. Life expectancy of \>3 months. 6. Karnofsky performance status \>70%. 7. The patient shows normal organ function according to the following parameters(as measured within six weeks prior to treatment allocation):
• •Hemoglobin: Within normal range according to institutional standards;
• •Absolute leukocyte count: Within normal range according to institutional standards;
• •Absolute lymphocyte count: Within normal range according to institutional standards;
• •Platelet count: Within normal range according to institutional standards;
• •Alanine aminotransferase: ≤ 2.5 x Upper Limit of Normal (ULN);
• •Aspartate aminotransferase: ≤ 2.5 x ULN;
• •Total bilirubin: ≤ 1.5 x ULN. In the case of known Gilbert's syndrome ≤ 2 x ULN;
• •Serum creatinine: 1.5 x ULN;
• •Calculated creatinine clearance: \> 50 mL/min . 8. Age \>18 years. 9. No history of autoimmune diseases. 10. Ability to understand the study protocol and a willingness to sign a written informed consent document.